Opioid-induced constipation can be a frustrating and debilitating side effect of pain management. Fortunately, medical professionals now have access to naloxegol, a medication that specifically targets this issue. In this comprehensive guide, we'll unpack everything you need to know about naloxegol, including its pros and cons, potential side effects, and cost. By the end of this article, you'll have a thorough understanding of how naloxegol works and whether it's the right treatment option for your patients with opioid-induced constipation. So let's dive in!
Naloxegol, also known as Movantik, is a medication used to treat opioid-induced constipation. While it has been proven effective in relieving constipation symptoms caused by opioids, like any other medication, it has its pros and cons.
One of the main advantages of Naloxegol is that it works by blocking the opioid receptors in the gut without affecting pain relief. This means that patients can continue taking their prescribed opioids while also managing their constipation symptoms.
Another advantage is that Naloxegol has a lower risk of abuse than other medications for constipation relief because it does not produce a high or euphoric effect.
On the downside, some common side effects of Naloxegol include abdominal pain, diarrhea, nausea, vomiting and headaches. In rare cases, patients may experience severe allergic reactions which require immediate medical attention.
Another disadvantage is that Naloxegol should be used with caution in patients with liver problems or those taking medications metabolized by CYP3A4 enzymes because it may increase drug levels in the blood leading to potential adverse drug interactions.
Naloxegol is an effective medication for treating opioid-induced constipation, but like any other drug, it comes with potential side effects. While most patients tolerate naloxegol well, some may experience adverse reactions.
One of the most common side effects of Naloxegol is nausea. Patients may feel queasy and uncomfortable after taking the medication. Other gastrointestinal symptoms like diarrhea, vomiting and abdominal pain have also been reported in some cases.
In rare instances, naloxegol can lead to severe allergic reactions such as hives or swelling of the face. In case this happens to a patient, immediate medical attention should be sought.
Some people may also experience headaches while using naloxegol. Dizziness and fatigue are other possible side effects that could affect daily activities.
Naloxegol is a promising medication for managing opioid-induced constipation in patients who are not responding well to other laxatives. It has been shown to be effective and generally safe with few side effects.
As medical professionals, it is important to understand the pros and cons of using naloxegol as part of our treatment strategies. We must monitor our patients closely for any potential side effects and educate them on how to properly use the medication.
Naloxegol offers another option for managing opioid-induced constipation and can greatly improve the quality of life for those suffering from this condition.
1.
The clinical trial of ENZAMET shows promise as a treatment for prostate cancer.
2.
Lung Cancer Screening Rates in Eligible Adults Remain Low, Uneven
3.
TikTok creators perform 'roles' when sharing their hereditary cancer stories, shaping the health information they share
4.
It Is Not Just the Royals Who Go Through Cancer.
5.
Joe Biden has prostate cancer with bone spread. An oncologist explains what you need to know
1.
Unlocking the Potential of Leukemia Treatment: A New Hope for Patients
2.
Managing KRAS Inhibitor Toxicities: Focus on Rash and Beyond
3.
ERASur: Evaluating Total Ablative Therapy in Limited Metastatic Colorectal Cancer
4.
Oncology Partnerships: Driving Innovation Through Strategic Collaborations and Pharma Engagement USA
5.
Omega-3 Fatty Acids as Molecular Adjuvants Against Chemoresistance in Breast Cancer
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
4.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
5.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation